|
G5: pma/510(k)#: k021954, k022172, k023273, k023301, k024152, k030677, k031306, k031679, k031679, k032131, k033784, k033907, k040006, k040106, k040716, k050555, k051689, k053241, k060214, k060217, k060218, k060218, k060493, k082538, k082852, k082913 h.3.A device evaluation and/or device history review is anticipated but is not complete.Upon completion, a supplemental report will be filed.
|
|
The following information has been updated with corrected and/or additional information: b.5.Describe event or problem: it was reported while using bd phoenix¿ pmic/id-106 that there was a false resistant result reported out on one patient.Customer is unable to confirm if there was patient impact.H.6.Investigation summary: this complaint is for high mic results for vancomycin (va) when using phoenix panel pmic/id-106 (catalog number 448606) batch number 3150521.The customer did not provide panel returns, isolates or lab reports but provided binary files for the investigation.To investigate, three retention samples each from complaint batch 3150521 were inoculated with qc isolates staphylococcus aureus a29213 and enterococcus faecalis a29212 to observe for va mic results.The investigation returned all six panels with satisfactory va mic results, therefore this complaint is not confirmed.A review of the binary files was determined not to be required based on the results of the investigation.For further investigation, the batch history records were satisfactory and no quality notifications were generated during manufacturing and inspection.Complaint trending was performed and no trends were identified associated with this defect.Bd will continue to monitor for trends and take action as necessary.Please continue to communicate any additional concerns.
|